News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Weak market sentiment creates a buying window in Intuitive Machines (LUNR).
  • Company's tangible backlog provides near-term revenue visibility.
  • Growing satellite manufacturing traction improves execution potential.
  • Valuation appears to discount successful execution, implying upside.
  • Recommended trade: enter at $10.75, stop $8.50, target $22 over 180 trading days.
  • Primary catalysts are backlog conversion and scaling of satellite manufacturing.
  • Primary risks are execution delays and contract slippage that would undermine the thesis.

Latest Articles

SIRI: YouTube Deal Turns a 'Value Trap' Into a Tactical Long

SIRI: YouTube Deal Turns a 'Value Trap' Into a Tactical Long

SiriusXM's exclusive U.S. audio-ad representation deal with YouTube is beginning to re-price the company from sleepy satellite-radio utility into a scalable ad-platform play. The shares still trade cheaply on multiple metrics, provide a 3.7% dividend yield, and have operational optionality via Pandora and podcasts. This trade idea outlines an actio…

Herbalife Announces $250 Million Share Repurchase; Stock Climbs 5%

Herbalife Announces $250 Million Share Repurchase; Stock Climbs 5%

Herbalife Nutrition Ltd. said its board approved a $250 million share repurchase program that will run for three years, enabling purchases via open market transactions, negotiated deals and accelerated share repurchases. Shares rose about 5% on the announcement. Management cited confidence in the company's financial profile, free cash flow generati…

Polar Power Reduces Pinnacle Bank Debt by $3 Million, from Approximately $4.7 Million to $1.667 Million; Expects Remaining Balance to Be Paid Down by End of September

Polar Power Reduces Pinnacle Bank Debt by $3 Million, from Approximately $4.7 Million to $1.667 Million; Expects Remaining Balance to Be Paid Down by End of September

Polar Power, Inc. has successfully reduced its outstanding Pinnacle Bank debt by approximately $3 million, lowering the balance from $4.7 million to about $1.667 million as of September 2026. The company expects to fully repay the remaining balance by the end of September, substantially improving its financial flexibility and positioning for future…

D-Wave Gains After Securing Up to $100M in CHIPS Act Support

D-Wave Gains After Securing Up to $100M in CHIPS Act Support

D-Wave Quantum shares rose 4.5% on Tuesday after the company finalized a definitive agreement with the U.S. Department of Commerce to receive up to $100 million in CHIPS and Science Act funding. The financing is earmarked for research and development across D-Wave’s superconducting annealing and gate-model platforms and is tied to a minority, non-c…

Pharvaris Shares Jump After Positive Phase 3 Results for Deucrictibant XR

Pharvaris Shares Jump After Positive Phase 3 Results for Deucrictibant XR

Pharvaris saw its stock climb 27% after reporting topline results from CHAPTER-3, a global Phase 3 study of deucrictibant XR for preventing hereditary angioedema attacks. The trial met its primary endpoint with an 83% reduction in attack rate versus placebo, including an 87% reduction in participants with HAE Type 1 or Type 2. The company says the …

Shelters on Mexico’s Northern Border See Sharp Decline as Migration to U.S. Slows

Shelters on Mexico’s Northern Border See Sharp Decline as Migration to U.S. Slows

Migrant reception centers along Mexico's northern frontier have seen a marked drop in occupancy as stricter U.S. immigration measures and a stepped-up deportation campaign discourage attempts to cross. In Ciudad Juarez, a handful of migrants remain in local shelters while many facilities report low use and changing resident profiles, with most occu…

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

Zenas BioPharma announced a virtual investor event to discuss Obexelimab, its lead drug candidate for treating Immunoglobulin G4-Related Disease (IgG4-RD). The event will cover disease overview, treatment landscape, and the company's commercial strategies ahead of potential FDA approval. The FDA has accepted Zenas' Biologics License Application for…

Lantronix CEO to Participate in Upcoming Investor and Industry Events

Lantronix CEO to Participate in Upcoming Investor and Industry Events

Lantronix Inc., a leader in Edge AI and Industrial IoT solutions, announced that CEO Saleel Awsare will participate in several upcoming investor and industry events focused on government, defense technology, aerospace, and unmanned systems. These appearances aim to highlight Lantronix's capabilities in NDAA-compliant unmanned systems and critical i…

American Electric Power: Positioned to Ride the AI-Driven Grid Upgrade

American Electric Power: Positioned to Ride the AI-Driven Grid Upgrade

AEP offers a conservative-growth utility play with a 3%+ yield, visible rate-base expansion and a dominant transmission franchise exposed to AI data-center load. Valuation is reasonable at ~21.6x earnings and a $67.8B market cap; catalysts around contracted capacity and an elevated capital plan could drive re-rating. Trade plan provided for a long-…

Invivyd to Participate in Upcoming September Investor Conferences

Invivyd to Participate in Upcoming September Investor Conferences

Invivyd, Inc., a biopharmaceutical company focused on viral infectious diseases, announced management's participation in three prominent September 2026 investor conferences including Citi’s Biopharma Back to School, Cantor Global Healthcare, and H.C. Wainwright Annual Global Investment Conferences, featuring fireside chats and investor meetings. Th…

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

Kura Oncology has appointed Jennifer Fulk as Chief Financial Officer, bringing over 20 years of extensive biopharmaceutical finance experience. Ms. Fulk’s expertise spans commercial operations, R&D portfolio management, investor relations, and capital allocation. This leadership addition is expected to support Kura's commercial expansion of KOMZIFT…

Lightbridge Letter to Shareholders Outlines Expedited Pathway to Bring Lightbridge Fuel™ to Commercial Reactors

Lightbridge Letter to Shareholders Outlines Expedited Pathway to Bring Lightbridge Fuel™ to Commercial Reactors

Lightbridge Corporation announced its selection for the U.S. Department of Energy's Launch Pad INL Program, enabling an expedited two-pronged strategy to commercialize its advanced Lightbridge Fuel™. The Special HALEU Extrusion Demonstration (SHED) facility at Idaho National Laboratory will produce Lead Test Assemblies under DOE authorization, acce…

Rigetti Signs Definitive Agreement for $100M with U.S. Government to Accelerate R&D for Superconducting Quantum Computing

Rigetti Signs Definitive Agreement for $100M with U.S. Government to Accelerate R&D for Superconducting Quantum Computing

Rigetti Computing announced a definitive agreement with the U.S. Department of Commerce for $100 million in funding under the CHIPS Act to accelerate research and development in superconducting quantum computing. The funding will support three key R&D projects focused on scaling quantum computers and advancing Rigetti's roadmap to commercial utilit…

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

Adlai Nortye Group Ltd. has dosed the first patient in Australia and received U.S. FDA clearance to begin a global Phase I clinical trial of AN4035, a first-in-class CEACAM5-targeting antibody-drug conjugate armed with a pan-RAS(ON) inhibitor designed for tumor-selective delivery. The trial will evaluate AN4035's safety, pharmacokinetics, and preli…